Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "innovation"

2400 News Found

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
Clinical Trials | March 03, 2026

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population


Zenex Animal Health makes strategic European play with VievePharm acquisition
Healthcare | March 02, 2026

Zenex Animal Health makes strategic European play with VievePharm acquisition

VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets


Novo Nordisk invests €432 million to expand Athlone facility for global Wegovy pill supply
News | March 02, 2026

Novo Nordisk invests €432 million to expand Athlone facility for global Wegovy pill supply

The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202


Emcure partners with Roche to boost nephrology and transplant care in India
News | March 02, 2026

Emcure partners with Roche to boost nephrology and transplant care in India

Emcure to distribute Roche's kidney transplant and anemia drugs in India


Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS
Clinical Trials | March 02, 2026

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology


Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access
People | February 28, 2026

Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access

Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy


FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer
Drug Approval | February 28, 2026

FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy